BioLargo Subsidiary Clyra Advances ViaCLYR Evaluations With US Health Systems

Bitget2026/11/02 13:42

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioLargo subsidiary Clyra Medical is advancing ViaCLYR through clinical evaluations and approval processes at several US healthcare systems.
The most advanced discussions involve a system operating almost 20 hospitals and 200 clinics.
ViaCLYR, an FDA-cleared wound irrigation solution, has treated hundreds of patients since its March 2026 commercial launch.
Distributor Advanced Solution provides access to approximately 85% of the US market; Al Hikma covers 18 Middle Eastern countries, with registrations underway.
Clyra is preparing to launch an additional product line with a confidential strategic partner.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLargo Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioLargo Subsidiary Clyra Advances ViaCLYR Evaluations With US Health Systems

You may also like

Crypto prices